Human monoclonal antibody against Hepatitis B virus surface antigen (HBsAg)

Antiviral Research

Volumn 75, Issue 2, 2007, Pages 113-120

  Shin, Yong Won ^a   Ryoo, Kyung Hwan ^a   Hong, Kwang Won ^a   Chang, Ki Hwan ^a   Choi, Jin Seol ^a   So, Minyoung ^a   Kim, Pan Kyung ^a   Park, Jie Young ^a   Bong, Ki Tae ^a   Kim, Se Ho ^a  

^a Green Cross Company   (South Korea)

Author keywords

Chinese hamster ovary (CHO) cell; Hepatitis B immune globulin (HBIG); Hepatitis B virus (HBV); Hepatitis B virus surface antigen (HBsAg); Human antibody; Tissue cross reactivity

Indexed keywords

HEPABIG; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; VIRUS PARTICLE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY REACTIONS; CHO CELLS; CRICETINAE; CRICETULUS; CROSS REACTIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS;

CRICETULUS GRISEUS; HEPATITIS B VIRUS;

EID: 34247633520     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.01.005     Document Type: Article

References (34)

1. Alexopoulou A., Karayiannis P., Hadziyannis S.J., Aiba N., and Thomas H.C. Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J. Hepatol. 26 (1997) 748-753
2. Baca M., Presta L.G., O'Connor S.J., and Wells J.A. Antibody humanization using monovalent phage display. J. Biol. Chem. 272 (1997) 10678-10684
3. Carman W.F., Jacyna M.R., Hadziyannis S., Karayiannis P., McGarvey M.J., Makris A., and Thomas H.C. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2 (1989) 588-591
4. Chiou H.L., Lee T.S., Kuo J., Mau Y.C., and Ho M.S. Altered antigenicity of 'a' determinant variants of hepatitis B virus. J. Gen. Virol. 78 (1997) 2639-2645
5. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathology. Springer Semin. Immunopathol. 17 (1995) 261-281
6. Cirera I., Mas A., Salmeron J.M., Jimenez D.F., Sanjose A., Navasa M., Rimola A., Roca M., Grande L., Garcia-Valdecasas J.C., and Rodes J. Reduced doses of hepatitis B immunoglobulin protect against Hepatitis B virus infection recurrence after liver transplantation. Transpl. Proc. 33 (2001) 2551-2553
7. Day Y.S., Baird C.L., Rich R.L., and Myszka D.G. Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods. Protein Sci. 11 (2002) 1017-1025
8. Ehrlich P.H., Moustafa Z.A., Justice J.C., Harfeldt K.E., Kelley R.L., and Ostberg L. Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum. Antibodies Hybridomas. 3 (1992) 2-7
9. Eren R., Ilan E., Nussbaum O., Lubin I., Terkieltaub D., Arazi Y., Ben-Moshe O., Kitchinzky A., Berr S., Gopher J., Zauberman A., Galun E., Shouval D., Daudi N., Eid A., Jurim O., Magnius L.O., Hammas B., Reisner Y., and Dagan S. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 32 (2000) 588-596
10. Eren R., Lubin I., Terkieltaub D., Ben-Moshe O., Zauberman A., Uhlmann R., Tzahor T., Moss S., Ilan E., Shouval D., Galun E., Daudi N., Marcus H., Reisner Y., and Dagan S. Human monoclonal antibodies specific to Hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system. Immunology 93 (1998) 154-161
11. Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clin. Chem. 43 (1997) 1500-1506
12. Green L.L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231 (1999) 11-23
13. Han S.H., Ofman J., Holt C., King K., Kunder G., Chen P., Dawson S., Goldstein L., Yersiz H., Farmer D.G., Ghobrial R.M., Busuttil R.W., and Martin P. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 6 (2000) 741-748
14. Heijtink R., Paulij W., van Bergen P., van Roosmalen M., Rohm D., Eichentopf B., Muchmore E., de Man R., and Osterhaus A. In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J. Gen. Virol. 80 (1999) 1529-1535
15. Hong H.J., Ryu C.J., Hur H., Kim S.H., Oh H.K., Oh M.S., and Park S.Y. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318 (2004) 134-141
16. Hoogenboom H.R., and Chames P. Natural and designer binding sites made by phage display technology. Immunol. Today 21 (2000) 371-378
17. Ijaz S., Ferns R.B., and Tedder R.S. A 'first loop' linear epitope accessible on native hepatitis B surface antigen that persists in the face of 'second loop' immune escape. J. Gen. Virol. 84 (2003) 269-275
18. Keller M.A., and Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13 (2000) 602-614
19. Kim S.H., and Park S.Y. Selection and characterization of human antibodies against hepatitis B virus surface antigen (HBsAg) by phage-display. Hybrid Hybridomics 21 (2002) 385-392
20. Lok A.S. Hepatitis B infection: pathogenesis and management. J. Hepatol. 32 (2000) 89-97
21. Mountain A., and Adair J.R. Engineering antibodies for therapy. Biotechnol. Genet. Eng. Rev. 10 (1992) 1-142
22. Nakamura K., Tanaka Y., Shitara K., and Hanai N. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol. Immunother. 50 (2001) 275-284
23. Nguyen H., Sandhu J., and Hozumi N. Production of human monoclonal antibodies in SCID mouse. Microbiol. Immunol. 41 (1997) 901-907
24. Nieba L., Krebber A., and Plückthun A. Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal. Biochem. 234 (1996) 155-165
25. Paar D.P., Montgomerie B.M., Nadler P., Schiff E.R., and Pollard R.B. A phase I/II open-label study to assess the safety, pharmacokinetic profile, and preliminary antiviral effects of ost-577 (a human anti-hepatitis b surface antigen monoclonal antibody) administered to patients who are persistently hepatitis B antigen seropositive. The 7th International Conference on Antiviral Research. Charleston, South Carolina, February 27-March 4, 1994. Antiviral Res. 23 Suppl. 1 (1994) 81
26. Peterson D.L., Nath N., and Gavilanes F. Structure of hepatitis B surface antigen. Correlation of subtype with amino acid sequence and location of the carbohydrate moiety. J. Biol. Chem. 257 (1982) 10414-10420
27. Reisner Y., and Dagan S. The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases. Trends Biotechnol. 16 (1998) 242-246
28. Ryu C.J., Padlan E.A., Jin B.R., Yoo O.J., and Hong H.J. A humanized antibody with specificity for hepatitis B surface antigen. Hum. Antibodies Hybridomas. 7 (1996) 113-122
29. Saab S., Kim M., Wright T.L., Han S.H., Martin P., and Busuttil R.W. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 119 (2000) 1382-1384
30. Sawyer L.A. Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 47 (2000) 57-77
31. Stirk H.J., Thornton J.M., and Howard C.R. A topological model for hepatitis B surface antigen. Intervirology 33 (1992) 148-158
32. Urlaub G., Mitchell P.J., Kas E., Chasin L.A., Funanage V.L., Myoda T.T., and Hamlin J. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat. Cell Mol. Genet. 12 (1986) 555-566
33. Vaswani S.K., and Hamilton R.G. Humanized antibodies as potential therapeutic drugs. Ann. Allergy Asthma Immunol. 81 (1998) 105-119
34. Witherell G. Curr. Opin. Investig. Drugs 3 (2002) 684-692